June 30, 2016
Steven Goldman reappointed as codirector of Center for Translational Neuromedicine, Dean Zutes Chair
Steven Goldman, professor of neurology, has been reappointed as codirector of the Center for Translational Neuromedicine and as the Dean Zutes Chair in Biology of the Aging Brain—both through June 30, 2020. Goldman also retains his joint appointments as professor of neurosurgery and as Distinguished Professor in Neurosciences.
Goldman is interested in cell genesis and neural regeneration in the adult brain. His lab focuses on the use of stem and progenitor cells for the treatment of neurodegenerative disorders such as Huntington's Disease, as well as for the treatment of glial diseases such as the pediatric leukodystrophies and multiple sclerosis. He has published more than 250 papers in his field—more than 100 as first or senior author—as well as 20 issued patents with more pending.
June 7, 2016
Researchers have successfully reduced the symptoms and slowed the progression of Huntington's disease in mice using healthy human brain cells. The findings, which were published today in the journal Nature Communications, could ultimately point to a new method to treat the disease.
The research entailed implanting the animals with human glia cells derived from stem cells. One of the roles of glia, an important support cell found in the brain, is to tend to the health of neurons and the study's findings show that replacing sick mouse glia with healthy human cells blunted the progress of the disease and rescued nerve cells at risk of death.
The role that glia cells play in the progression of Huntington's disease has never really been explored,said Steve Goldman, M.D., Ph.D., co-director of the University of Rochester Center for Translational Neuromedicine.
This study shows that these cells are not only important actors in the disease, but may also hold the key to new treatment strategies.
February 22, 2016
In a perspective piece appearing in the journal Cell Stem Cell, URMC neurologist Steve Goldman, M.D., Ph.D., lays out the current state of affairs with respect to stem cell medicine and how close we are to new therapies for neurological disorders.
The dawn of stem cell medicine some 25 years ago was greeted with great enthusiasm, particularly by scientists who study diseases in the central nervous system (CNS). Many of the diseases found in the brain and spinal cord are degenerative in nature; meaning that over time populations of cells are lost due to genetic factors, infection, or injury. Because stem cell medicine holds the potential to repair or replace damaged or destroyed cells, scientists have considered these diseases as promising candidates for new therapies.
However, as with other emerging fields of medicine, the race to cures has turned out to be more of marathon than a sprint. While scientists have become very adept at manipulating stem and progenitor cells and understanding the complex choreography of genetic and chemical signals that instruct these cells to divide, differentiate, and proliferate, researchers are still grappling with the challenges of how to integrate new cells into the complex network of connections that comprise the human brain.
Goldman, co-director of the URMC Center for Translational Neuromedicine, takes a sweeping view of where we stand and which CNS diseases may or may not ultimately benefit from future stem cell-based therapies.
- Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy.Cell Stem Cell. (2016 Aug 09).
- PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.Oncogene. 35, 3817-28. (2016 Jul 21).
- Hdac3 Interaction with p300 Histone Acetyltransferase Regulates the Oligodendrocyte and Astrocyte Lineage Fate Switch.Dev Cell. 37, 582. (2016 Jun 20).